buff.ly/Fdy4n8H show manageable safety and encouraging survival outcomes, highlighting the potential of combining immunotherapy with chemotherapy in the adjuvant setting. #GastricCancer #Immunotherapy #Oncology #CancerResearch

This review explores how gut microbes may drive tumor initiation, progression, and therapy response - and how microbiome-targeted strategies could transform outcomes in one of the deadliest cancers. Read here 👉 buff.ly/dWH87rO #PancreaticCancer #Microbiome #Oncology #CancerResearch

Wrapping up an inspiring #SIBCS2025 in Shanghai. So many brilliant minds working to transform breast cancer care.

Thanks to everyone who stopped by booth #29 to chat about publishing with Sage Journals! #Oncology #BreastCancer #MedicalJournals

Kicking off #SIBCS2025 in Shanghai! Proud to represent Sage Publishing as Editor of Therapeutic Advances in Medical Oncology and Co-Editor of Clinical Medicine Insights: Oncology + Rare Tumors.

Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch

ADCs are transforming breast cancer care, but toxicity management remains key to patient outcomes. Read the full review 👉 buff.ly/Fp2c5JI #BreastCancer #Oncology #ADCs #CancerResearch

📊 Real-world data from Spain shows that nal-IRI + 5-FU/LV offers survival benefits for patients with advanced #PDAC, with outcomes comparable to clinical trials.
Dive into the full TAMO study: buff.ly/hOvxr4Q
#PancreaticCancer #RealWorldEvidence #TAMO #ESMO25 #OncologyResearch

As #ESMO25 wraps up, we celebrate the science - and the people behind it.
Huge congratulations to TAM Associate Editor Dr. Natasha Leighl on receiving the Women for Oncology Award!
A true leader in cancer care. 👏
#WomenInSTEM #OncologyLeadership

@tamedoncol.bsky.social
Navigating the Roadmap of New Treatment Options in HR+HER2- Advanced BC
Despite major advances, metastatic HR+HER2- BC remains incurable.
This Collection invites original research, reviews & meta-analyses
Deadline: Dec 01, 2025
🔗 buff.ly/etMC9S7
#Oncology #BreastCancer

Zolbetuximab is gaining attention as a targeted therapy for CLDN18.2-positive gastric and GEJ cancers.
This review dives into the science behind Claudin18.2 and the clinical promise of zolbetuximab, backed by SPOTLIGHT and GLOW trial data.
buff.ly/ok6eO7y
#Oncology #GastricCancer #Zolbetuximab

Lung cancer is varying by region in risks and traits. A new article examines carcinogens, genetic predisposition, and molecular epidemiology. We seek submissions on geographic differences in lung cancer. Deadline: Dec 31, 2025 🔗 buff.ly/JCo9lJP #CancerResearch #LungCancer #GlobalHealth

🚨Call for Papers: @tamedoncol.bsky.social invites submissions on Antibody Drug Conjugates (ADCs) in Gynecologic Cancers. Led by Dr. Angélica Nogueira Rodrigues & Dr. Rowan Miller, this collection spotlights innovative ADC research in gynecologic oncology. 📥 Submit your work. buff.ly/RhdEIHX

🌟 Discover our top-cited article at @tamedoncol.bsky.social on aberrant DNA methylation in cancer. This review delves into epigenetic influences from BRCA1 to ctDNA, highlighting diagnostic, prognostic, and therapeutic impacts. 📖 Read more 🌟 buff.ly/ZAp0iD3

🌟 Most cited in its year!
Explore Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4 in @tamedoncol.bsky.social. This review highlights promising multivariate assays like ROMA, OVA1 & Overa that could transform early OC detection.
📖 Read the article buff.ly/49NiTuO

🌟 New Special Collection! 🌟

"Navigating New Treatment Options in HR+HER2- Advanced Breast Cancer" is now open for submissions. We invite researchers and clinicians to share their insights.

🔗 Submit journals.sagepub.com/topic/collec...

Join us to improve patient care and outcomes. 🚀